Infection of HHV-8+ primary effusion lymphoma cells with a recombinant Epstein-Barr virus leads to restricted EBV latency, altered phenotype, and increased tumorigenicity without affecting TCL1 expression

Blood

Volumn 103, Issue 1, 2004, Pages 313-316

  Trivedi, Pankaj ^a   Takazawa, Kumi ^b   Zompetta, Claudia ^b   Cuomo, Laura ^b   Anastasiadou, Elena ^b   Carbone, Antonino ^b   Uccini, Stefania ^b   Belardelli, Filippo ^b   Takada, Kenzo ^b   Frati, Luigi ^b   Faggioni, Alberto ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD30 ANTIGEN; CD74 ANTIGEN; GENE PRODUCT; MEMBRANE ANTIGEN; PROTEIN EBER 1; PROTEIN EBNA 1; PROTEIN EBNA 2; PROTEIN EBNA 6; PROTEIN LMP1; PROTEIN LMP2A; PROTEIN LMP2B; SYNDECAN 1; T CELL LEUKEMIA 1 PROTEIN; TUMOR PROTEIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENICITY; CLONE; CONTROLLED STUDY; DOWN REGULATION; EPSTEIN BARR VIRUS; GENE EXPRESSION; HUMAN HERPESVIRUS 8; LYMPHOMA CELL; MOUSE; NONHUMAN; PATHOGENESIS; PHENOTYPE; PRIMARY EFFUSION LYMPHOMA; PRIORITY JOURNAL; SCID MOUSE; VIRUS INFECTION; VIRUS LATENCY; VIRUS RECOMBINANT; VIRUS STRAIN;

EID: 9144249086     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2003-05-1710     Document Type: Article

References (23)

1. Cesarman E, Chang Y, Moore PS, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus-like DNA sequences in AIDS-related body-cavity-based lymphomas. N Engl J Med. 1995;332:1186-1191.
2. Matolcsy A, Nador RG, Cesarman E, Knowles DM. Immunoglobulin VH gene mutational analysis suggests that primary effusion lymphomas derive from different stages of B cell maturation. Am J Pathol. 1998;153:1609-1614.
3. Nador RG, Cesarman E, Chadburn A, et al. Primary effusion lymphoma: a distinct clinicopathologic entity associated with the Kaposi's sarcoma-associated herpes virus. Blood. 1996;88:645-656.
4. Gaidano G, Carbone A. Primary effusion lymphoma: a liquid phase lymphoma of fluid-filled body cavities. Adv Cancer Res. 2001;80:115-146.
5. Cesarman E, Nador RG, Aozasa K, Delsol G, Said JW, Knowles DM. Kaposi's sarcoma-associated herpesvirus in non-AIDS related lymphomas occurring in body cavities. Am J Pathol. 1996;149:53-57.
6. Horenstein MG, Nador RG, Chadburn A, et al. Epstein-Barr virus latent gene expression in primary effusion lymphomas containing Kaposi's sarcoma-associated herpesvirus/human herpesvirus-8. Blood. 1997;90:1186-1191.
7. Szekely L, Chen F, Teramoto N, et al. Restricted expression of Epstein-Barr virus (EBV)-encoded, growth transformation-associated antigens in an EBV- and human herpesvirus type 8-carrying body cavity lymphoma line, J Gen Virol. 1998;79:1445-1452.
8. Wang D, Liebowitz D, Kieff E. An EBV membrane protein expressed in immortalized lymphocytes transforms established rodent cells, Cell. 1985;43:831-840.
9. Henderson S, Rowe M, Gregory C, et al. Induction of bcl-2 expression by Epstein-Barr virus latent membrane protein 1 protects infected B cells from programmed cell death. Cell. 1991;65:1107-1115.
10. Johannsen E, Miller CL, Grossman SR, Kieff E. EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes. J Virol. 1996;70:4179-4183.
11. Tierney RJ, Steven N, Young LS, Rickinson AB. Epstein-Barr virus latency in blood mononuclear cells: analysis of viral gene transcription during primary infection and in the carrier state. J Virol. 1994;68:7374-7385.
12. Rowe M, Rowe DT, Gregory CD, et al. Differences in B cell growth phenotype reflect novel patterns of Epstein-Barr virus latent gene expression in Burkitt's lymphoma cells. EMBO J. 1987;6:2743-2751.
13. Fahraeus R, Fu HL, Ernberg I, et al. Expression of Epstein-Barr virus-encoded proteins in nasopharyngeal carcinoma. Int J Cancer. 1988;42:329-338.
14. Klein G, Giovanella B, Westman A, Stehlin JS, Mumford D. An EBV-genome-negative cell line established from an American Burkitt lymphoma; receptor characteristics. EBV infectibility and permanent conversion into EBV-positive sublines by in vitro infection. Intervirology. 1975;5:319-334.
15. Cesarman E, Moore PS, Rao PH, Inghirami G, Knowles DM, Chang Y. In vitro establishment and characterization of two acquired immunodeficiency syndrome-related lymphoma cell lines (BC-1 and BC-2) containing Kaposi's sarcoma-associated herpesvirus-like (KSHV) DNA sequences. Blood. 1995;86:2708-2714.
16. Arvanitakis L, Mesri EA, Nador RG, et al. Establishment and characterization of a primary effusion (body cavity-based) lymphoma cell line (BC-3) harboring Kaposi's sarcoma-associated herpesvirus (KSHV/HHV-8) in the absence of Epstein-Barr virus. Blood. 1996;88:2648-2654.
17. Boshoff C, Gao SJ, Healy LE, et al. Establishing a KSHV' cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood. 1998;91:1671-1679.
18. Carbone A, Cilla AM, Gloghini A, et al. Characterization of a novel HHV-8-positive cell line reveals implications for the pathogenesis and cell cycle control of primary effusion lymphoma. Leukemia. 2000;14:1301-1309.
19. Yang L, Maruo S, Takada K. CD21-mediated entry and stable infection by Epstein-Barr virus in canine and rat cells. J Virol. 2000;74:10745-10751.
20. Shimizu N, Tanabe-Tochikura A, Kuroiwa Y, Takada K. Isolation of Epstein-Barr virus (EBV)-negative cell clones from the EBV-positive Burkitt's lymphoma (BL) line Akata: malignant phenotypes of BL cells are dependent on EBV. J Virol. 1994;68:6069-6073.
21. Trivedi P, Spinsanti P, Cuomo L, et al. Differential regulation of Epstein-Barr virus (EBV) latent gene expression in Burkitt lymphoma cells infected with a recombinant EBV strain. J Virol. 2001;75:4929-4935.
22. Komano J, Sugiura M, Takada K. Epstein-Barr virus contributes to the malignant phenotype and to apoptosis resistance in Burkitt's lymphoma cell line Akata. J Virol. 1998;72:9150-9156.
23. Kiss C, Nishikawa J, Takada K, Trivedi P, Klein G, Szekely L. T cell leukemia I (TCL-1) expression is dependent on the presence of the viral genome in EBV carrying Burkitt lymphoma lines. Proc Natl Acad Sci U S A. 2003;100:4813-4818.